ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.051 AUD -1.92% Market Closed
Market Cap: 103.2m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

ImpediMed Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ImpediMed Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
ImpediMed Ltd
ASX:IPD
Accounts Receivables
AU$2.2m
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
17%
R
Respiri Ltd
ASX:RSH
Accounts Receivables
AU$253.1k
CAGR 3-Years
23%
CAGR 5-Years
9%
CAGR 10-Years
12%
C
Cyclopharm Ltd
ASX:CYC
Accounts Receivables
AU$4.8m
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
4%
Cochlear Ltd
ASX:COH
Accounts Receivables
AU$490.7m
CAGR 3-Years
18%
CAGR 5-Years
9%
CAGR 10-Years
9%
Optiscan Imaging Ltd
ASX:OIL
Accounts Receivables
AU$1.6m
CAGR 3-Years
8%
CAGR 5-Years
30%
CAGR 10-Years
9%
EMvision Medical Devices Ltd
ASX:EMV
Accounts Receivables
AU$16.2k
CAGR 3-Years
N/A
CAGR 5-Years
-20%
CAGR 10-Years
N/A
No Stocks Found

ImpediMed Ltd
Glance View

Market Cap
103.2m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.08 AUD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is ImpediMed Ltd's Accounts Receivables?
Accounts Receivables
2.2m AUD

Based on the financial report for Jun 30, 2024, ImpediMed Ltd's Accounts Receivables amounts to 2.2m AUD.

What is ImpediMed Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
17%

Over the last year, the Accounts Receivables growth was -16%. The average annual Accounts Receivables growth rates for ImpediMed Ltd have been -8% over the past three years , 12% over the past five years , and 17% over the past ten years .

Back to Top